Role of P63 in Benign and Malignant Lesions of Breast
DOI:
https://doi.org/10.37506/ntjans24Keywords:
p63, Ductal carcinoma in situ, Fibroadenoma, Invasive ductal carcinoma, Myoepithelial cells.Abstract
Introduction: Breast carcinoma is leading cause of cancer death in women. Breast lesions constitute heterogeneous group of diseases with wide variety of etiologies ranging from inflammatory-benign- malignant lesions. There are several reported markers for immunohistochemical detection of myoepithelial cells. Smooth muscle specific proteins, such as smooth muscle actin, smooth muscle myosin heavy chain, calponin and h-caldesmon are used to highlight myoepithelium. p63 antibody is myoepithelial cell marker that selectively stains nuclei. It is negative in stromal, myofibroblastic and adipocytic cells.
Aims and Objectives: The aim of this study was to establish role of p63 expression in distinguishing benign breast lesions, premalignant lesions and malignant tumors of breast.
Materials and Methods: 30 cases were selected from core biopsy, lumpectomy and mastectomy specimens of
breast received at department of Pathology, Chalmeda Anand Rao Institute of Medical Sciences during the period of January 2021 to December 2021 and were studied prospectively. All specimens were processed according to CAP protocol and reported . Immunohistochemistry was performed to determine p63 expression in those specimens. p63 expression was evaluated as continuous positive/discontinuous positive/negative.
Ethical Approval: This study was reviewed and approved by institute ethics committee, CAIMS, Karimnagar.
Results: Among total 30 cases, 18 cases (60%) were benign lesions and all were positive for p63 expression. 3 cases (9.99%) were premalignant and were least positive for p63 expression. All malignant cases 9 cases (29.99%) were negative for p63 expression.
Conclusion: The Positive correlation was seen between histomorphological features and p63 scoring in all the lesions, So p63 is good Immunohistochemical marker for evaluating breast lesions.
References
Verma N, Sharma B, Singh P, Sharma SP, Rathi M,
Raj D. Role of p63 expression in non- proliferative
and proliferative lesions of breast. Int J Res Med
Sci.2018;6(8):2705-10.
Silva AR, Ramalho LNZ, Garcia SB, Zucoloto S. Is p63
reliable in detecting microinvasion in ductal carcinoma
in situ of the breast? Pathol Onchol Res. 2003;9(1): 20-3.
Khazai L, Rosa M. Use of immunohistochemical
stains in epithelial lesions of the breast. Cancer
control.2015;22(2):220-5.
Corben AD, Lerwill MF. Use of myoepithelial cell
markers in the differential diagnosis of benign, insitu
and invasive lesions of the breast. Int J Surg Pathol.
:351-73.
Barbareschi M, Pecciarini L, Cangi MG et al. p63,
a p53 homologue, is a selective nuclear marker of
myoepithelial cells of the human breast. Am J Surg
Pathol.2001;25(8):1054-60.
Wang et al. p63 expression in normal, hyperplastic
and malignant breast tiudsssue. Breast cancer.
;9(3):216-219.
Stefanou D, Batistatou A, Nonni A, Arkoumani E,
Agnantis NJ . p63 expression in benign and malignant
breast lesions. Histol Histopathol .2004;19:465-71.
Zaha DC. Significance of immunohistochemistry in
breast cancer. World J Clin Onchol.2014;5(3):382-92.
Abdallah DM, MF EI Deeb N. Comparative
immunohistochemical study of p63, SMA, CD10 and
calponin in distinguishing in situ from invasive breast
carcinoma. J Mol Biomark Diaagn. 2017;8(4): 2155-
Bibliography Page 91
Werling RW, Hwang H, Yaziji H, Gown AM.
Immunohistochemical distinction of invasive from
non-invasive breast lesions. A comparative study of
p63 versus calponin and smooth muscle myosin heavy
chain. Am J SurgPathol.2003;27(1):829.
Koker MM, Kleer CG. p63 expression in breast cancer
– A highly sensitive and specific marker of metaplastic
carcinoma. Am J Surg Pathol.200428(11):1506-12.
Ribeiro A, Ramalho LN, Garcia SB, Brandao DF,
Chahud F, Zucoloto S. p63 correlates with both BRCA1
and cytokeratin 5 in invasive breast carcinomas: further
evidence for the pathogenesis of the basal phenotype
of breast cancer. Histopathology. 2005;47(5):458-66.
Silva AR, Ramalho LNZ, Garcia SB, Zucoloto S. The
relationship between p63 and p53 expression in
normal and neoplastic breast tissue. Arch Pathol Lab
Med. 2003;127: 336-40.
Reisenbichler ES, Ross JR, Hameed O. The clinical use
of aP63/cytokeratin7/18/cytokeratin5/14 antibody
cocktail in diagnostic breast pathology.Ann Diag
Pathol.2014; 18(6): 313-8.
Moraes schenka NG, Schenka AA, De Souza Queiroz
L, De Almeida Matsura M, Vassallo J, Alvarenga M.
Use of p63 and CD10 in the differential diagnosis
of papillary neoplasms of the breast. Breast J.
;14(1):68-75.
Di Como et al. p63 expression in normal and tumor
tissues.2002.Clin. Cancer Res.2002;8:494-501.
Kaufmann O, Fietze E, Mengs J. Value of p63 and
cytokeratin 5/6 as immunohistochemical markers
for the differential diagnosis of poorly differentiated
and undifferentiated carcinomas. Am L Clin Pathol.
;116:823- 30.
Russell et al. Myoepithelial cell differentiation
markers in ductal carcinoma in situ progression. Am J
Pathol.2015;185:3076-89.
Moriya T, Kozuka Y, Kanomata n, Tse GM, Tan PH.
The role of immunohistochemistry in the differential
diagnosis of breast lesions. Pathology. 2009;41(1):68-71.
Gottlieb C, Raju U, Greenwald KA. Myoepithelial cells
in the differential diagnosis of complex benign and
malignant breast lesions: an immunohistochemical
study. Mod Pathol.2013;3:135-40.
Liu H. application of immunohistochemistry in breast
pathology. A review and update.2014;138:1629-42.
Zhao L, Yang X, khan A. Diagnostic role of
immunohistochemistry in the evaluation of
breast pathology specimens. Arch Pathol Lab
Med.2014;138(1):16- 24.
Shekhar MP, Kato I, Nangia-Makker P, Tait L.
Comedo-DCIS is a precursor lesion for basal-like
breast carcinoma: identification of a novel p63/
Her2/neu expressing subgroup. Oncotarget. 2013
Feb;4(2):231-41.
Gusterson BA et al. Distribution of myoepithelial cells
and basement membrane proteins in the normal breast
and in benign and malignant breast diseases. Cancer
Res. 2012;42:4763-4770.
Shamloula MM, Shorbagy SH, Saied EME. p63 and
cytokeratin 8/18 expression in breast atypical ductal
hyperplasia, ductal carcinoma in situ and invasive
duct carcinoma.Journal of Egyptian Nat. Cancer Inst.
;19(3):202-210.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.